Prediction of a clinically effective dose of THY1773, a novel V (1B) receptor antagonist, based on preclinical data

THY1773 is a novel arginine vasopressin 1B (V(1B)) receptor antagonist that is under development as an oral drug for the treatment of major depressive disorder (MDD). Here we report our strategy to predict a clinically effective dose of THY1773 for MDD in the preclinical stage, and discuss the impor...

Descripción completa

Detalles Bibliográficos
Autores principales: Inatani, Shoko, Mizuno‐Yasuhira, Akiko, Kamiya, Makoto, Nishino, Izumi, Sabia, Helene D., Endo, Hiromi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8252455/
https://www.ncbi.nlm.nih.gov/pubmed/33734452
http://dx.doi.org/10.1002/bdd.2273

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8252455/
https://www.ncbi.nlm.nih.gov/pubmed/33734452
http://dx.doi.org/10.1002/bdd.2273

Ejemplares similares